Manila Times Business
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
Agreement reinforces the value of UroGen’s innovation and reflects the strength of the Company’s intellectual property portfolioTeva will be granted a non-exclusive license to sell its generic version of JELMYTO beginning on September 15, 2030, if approved by the FDA PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announ
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Diamond drilling program under way at Leviathan Metals’ Central Project, Kalahari Copper Belt, Botswana
2h ago
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
2h ago
Paychex Small Business Jobs Index Improves for a Third Consecutive Month
2h ago
Safe Pro Awarded U.S. Army Order For AI-Powered Threat Analysis Kit Together with Red Cat Black Widow Drones
2h ago